Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148430 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2POLBRAB9AL3MBTL1HPGD | |
| SCHEMBL9137872 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBRAB9AL3MBTL1HPGD | |
| SCHEMBL30743612 | 0.86 | ABCG2 (0.55) | SMN1; SMN2POLBRAB9AL3MBTL1HPGD | |
| SCHEMBL4639478 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2POLBRAB9AL3MBTL1HPGD | |
| SCHEMBL28770200 | 0.85 | POLB (0.40) | SMN1; SMN2POLBRAB9AL3MBTL1HPGD | |
| SCHEMBL30676079 | 0.85 | HPGD (0.45) | SMN1; SMN2POLBRAB9AL3MBTL1HPGD | |
| SCHEMBL5091164 | 0.85 | POLB (0.43) | SMN1; SMN2POLBRAB9AL3MBTL1HPGD | |
| SCHEMBL4639604 | 0.85 | RAB9A (0.42) | SMN1; SMN2POLBRAB9AL3MBTL1HPGD | |
| SCHEMBL9136967 | 0.85 | POLB (0.46) | SMN1; SMN2POLBRAB9AL3MBTL1HPGD | |
| SCHEMBL6617494 | 0.85 | LMNA (0.46) | SMN1; SMN2POLBRAB9AL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0455423-B1 | Ortho-lithiation process for the synthesis of 2-substituted 1-(tetrazol-5-yl) benzenes | MERCK & CO INC (US) | 1996-12-18 | — | — | EP | claimed |
| EP-0455423-A2 | Ortho-lithiation process for the synthesis of 2-substituted 1-(tetrazol-5-yl) benzenes | MERCK & CO. INC. (US) | 1991-11-06 | — | — | EP | claimed |
| US-5039814-A | Chemical intermediates for angiotensin antagonist | MERCK & CO., INC. (US) | 1991-08-13 | — | — | US | claimed |
| EP-1384717-B1 | 2-(2'-triphenylmethyl-2'H-tetrazol-5'-yl)phenylboronic acid intermediates for the synthesis of A II receptor antagonists | DU PONT (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | CADILA PHARMACEUTICALS LTD. (IN) | 2007-10-25 | — | — | US | disclosed |
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | CADILA PHARMACEUTICALS LTD. (IN) | 2007-10-25 | — | — | US | disclosed |
| EP-1660463-A1 | A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES | Dipharma S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005014560-A1 | A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES | DIPHARMA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
| EP-0754042-A4 | TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | MERCK & CO INC (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1384717-A2 | Tetrazolylphenylboronic acid intermediates for the synthesis of A II receptor antagonists | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1019048-B1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | MERCK SHARP DOHME ITALIA S P A (IT) | 2004-01-21 | — | — | EP | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-5130439-A | Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists | E.I. DU PONT DE NEMOURS AND COMPANY, A CORPORATION OF DELAWARE | 1992-07-14 | — | — | US | disclosed |
| EP-0455423-A2 | Ortho-lithiation process for the synthesis of 2-substituted 1-(tetrazol-5-yl) benzenes | MERCK & CO. INC. (US) | 1991-11-06 | — | — | EP | disclosed |
| WO-1991015209-A1 | SUBSTITUTED PYRIMIDINES, PYRIMIDINONES AND PYRIDOPYRIMIDINES | MERCK & CO., INC. (US) | 1991-10-17 | — | — | WO | disclosed |
| US-5039814-A | Chemical intermediates for angiotensin antagonist | MERCK & CO., INC. (US) | 1991-08-13 | — | — | US | disclosed |
| US-4874867-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| US-4870186-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-09-26 | — | — | US | disclosed |
| US-4820843-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0291969-A2 | Tetrazole intermediates to antihypertensive compounds | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | AGTR1, REN, AGT | SMN1; SMN2 4434/4885POLB 3372/4885RAB9A 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.